MGC Pharmaceuticals Ltd. confirmed that it has completed production of the ?650,000 (AUD 1,000,000) ArtemiCTM order from Swiss PharmaCan AG, as first announced on 4 May 2021. Under the terms of the contract, MGC Pharma expects to receive the full order amount of ?650,000 (AUD 1,000,000) by early December, which would place the Company on track to deliver its best quarter and half yearly revenue result as at 31 December 2021. MGC Pharma are the sole producer of ArtemiCTM and SPC, the master distributors. MGC Pharma has existing food supplement manufacturing capacity in Slovenia to produce this and future orders from SPC, which are progressing access to new markets following the September grant of the Certificate of Free Trade in Germany and the EU. MGC Pharma and SPC are continuing to seek approvals for ArtemiCTM as a supplement in a number of countries to provide support to COVID-19 patients and alleviate their symptoms. Alongside this, MGC Pharma are making progress on the long-term development of the Investigational Medicinal Product CimetrATM through its ongoing clinical studies, and applications for Emergency Use Authorisation in India and other National Regulatory and Medical Agencies are currently underway.